Tag Archives: Biotech

Uncertain Outlook for Pharma and Biotech Deals Following 'Turbulent' 2011

Peter Young, President and Managing Director of international investment bank Young & Partners, looks at what lies ahead for pharma and biotech following a turbulent 2011. The business outlook for pharma companies for the rest of 2012 and beyond is mixed, as pharma companies struggle to realign themselves to a new business model that will […]
Posted in Global, Guest Blog, leadership, Strategy | Also tagged , , , , | Leave a comment

VC Funding Floods Colorado Biotechs, But Will It Stifle Innovation?

By Marylyn Donahue. Biotechs in Colorado, US, are enjoying a windfall of funding from Venture Capitalists who have to date invested $66.1 million in six of the state’s companies working in the fields of biofuel, medical devices and biopharma, according to a report released Feb 21 by OnBioVC, a Boulder-based tracker of investments in the […]
Posted in Biotech, Deals, Guest Blog | Also tagged , , , , , , | Leave a comment

Shrinking Economy Hits California Biosector

By Amy Ritter, Pharmaeutical Technology. A report released on Feb. 8, 2012 from the California Healthcare Institute, BayBio and PwC shows that the shrinking economy, changes in investment strategies, and pressures on the pharmaceutical market have put the brakes on one of the US’s most robust biotechnology centers. California had enjoyed steady growth in its […]
Posted in Biotech, Guest Blog | Also tagged , , , | Leave a comment

California Life Sciences to Partner with China

BIOCOM, a trade group representing Southern California’s life sciences industry, is ramping up partnership efforts in China to meet an emerging desire for novel drug therapies. While intellectual property (IP) protections and the Chinese government’s willingness to pay for expensive new products represent two large and lingering question marks, Joe Panetta, president and CEO at […]
Posted in Biotech, Emerging Markets, Global, IP, leadership, Market Access, R&D | Also tagged , , , | Leave a comment

Gilead Buys CV Therapeutics (Update 1)

The morning’s other big M&A news comes out of the Bay Area biotech industry, where Gilead Sciences announced that it will purchase CV Therapeutics for $1.4 billion. The sudden move frees Palo Alto-based cardiovascular company CV Therapeutics from the hostile embrace of Astellas Pharma, ending a messy $1.1 billion takeover attempt. With the acquisition, Gilead, […]
Posted in Deals | Also tagged , , , , , , | 3 Comments
  • Categories

  • Meta